Osimertinib companion diagnostic - AstraZeneca/Roche

Drug Profile

Osimertinib companion diagnostic - AstraZeneca/Roche

Alternative Names: cobas EGFR Mutation Test v2; Mereletinib companion diagnostic - AstraZeneca/Roche

Latest Information Update: 03 Oct 2016

Price : $50

At a glance

  • Originator AstraZeneca; Roche
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Non-small cell lung cancer

Most Recent Events

  • 29 Sep 2016 US FDA approves Osimertinib companion diagnostic for use with plasma samples for Non-small cell lung cancer (Diagnosis) in USA
  • 15 Mar 2016 Biomarkers information updated
  • 13 Nov 2015 Registered for Non-small cell lung cancer (Diagnosis) in USA - first global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top